elranatamab,ixazomib,mezigdomide,tocilizumab,daratumumab,thalidomide,pomalidomide,bortezomib
pfizer,takeda,janssen,roche,bms,allogene therapeutics,emergent biosolutions
['toci', 'ixazomib', 'mmsm', 'magnetismm-1', 'thalidomide', 'daratumumab', 'bortezomib', 'pomalidomide', 'cc-92480', 'elranatamab', '2019', 'borte', 'emergent ', 'imab ']
#ash22 #mmsm elranatamab- magnetismm-1 safety concerns. infections. investigators need to call infections happening on ttt as related to ttt (one g5 adenovirus infection) see data below table orr: 64%, prior bcma (~50%) was used in some pts (swimmer plot). dor ~1.5 yr 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities